ID   MK03_HUMAN              Reviewed;         379 AA.
AC   P27361; A8CZ58; B0LPG3; Q8NHX1;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 199.
DE   RecName: Full=Mitogen-activated protein kinase 3;
DE            Short=MAP kinase 3;
DE            Short=MAPK 3;
DE            EC=2.7.11.24;
DE   AltName: Full=ERT2;
DE   AltName: Full=Extracellular signal-regulated kinase 1;
DE            Short=ERK-1;
DE   AltName: Full=Insulin-stimulated MAP2 kinase;
DE   AltName: Full=MAP kinase isoform p44;
DE            Short=p44-MAPK;
DE   AltName: Full=Microtubule-associated protein 2 kinase;
DE   AltName: Full=p44-ERK1;
GN   Name=MAPK3; Synonyms=ERK1, PRKM3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hepatoma;
RX   PubMed=7687743; DOI=10.1128/MCB.13.8.4679;
RA   Charest D.L., Jirik F., Harder K., Pelech S.L., Mordret G.;
RT   "Molecular cloning, expression, and characterization of the human
RT   mitogen-activated protein kinase p44erk1.";
RL   Mol. Cell. Biol. 13:4679-4690(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Aebersold D.M., Yung Y., Seger R.;
RT   "Properties of human ERK1b.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Cheng H., Ren S., Qiu R., Wang M., Feng Y.H.;
RT   "Identification of dominant negative Erk1/2 variants in cancer
RT   cells.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-15; 33-41; 88-94; 117-131; 212-220; 279-287;
RP   303-318 AND 360-370, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Dhillon A.S., Kolch W.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-379 (ISOFORM 1).
RX   PubMed=1540184; DOI=10.1016/0006-291X(92)91891-S;
RA   Owaki H., Makar R., Boulton T.G., Cobb M.H., Geppert T.D.;
RT   "Extracellular signal-regulated kinases in T cells: characterization
RT   of human ERK1 and ERK2 cDNAs.";
RL   Biochem. Biophys. Res. Commun. 182:1416-1422(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 25-379 (ISOFORM 1).
RX   PubMed=1319925; DOI=10.1016/0014-5793(92)80612-K;
RA   Gonzalez F.A., Raden D.L., Rigby M.R., Davis R.J.;
RT   "Heterogeneous expression of four MAP kinase isoforms in human
RT   tissues.";
RL   FEBS Lett. 304:170-178(1992).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF STMN1.
RX   PubMed=8325880;
RA   Marklund U., Brattsand G., Shingler V., Gullberg M.;
RT   "Serine 25 of oncoprotein 18 is a major cytosolic target for the
RT   mitogen-activated protein kinase.";
RL   J. Biol. Chem. 268:15039-15047(1993).
RN   [12]
RP   INTERACTION WITH HIV-1 NEF.
RX   PubMed=8794306;
RA   Greenway A.L., Azad A., Mills J., McPhee D.A.;
RT   "Human immunodeficiency virus type 1 Nef binds directly to LCK and
RT   mitogen-activated protein kinase, inhibiting kinase activity.";
RL   J. Virol. 70:6701-6708(1996).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF MKNK1/MNK1.
RX   PubMed=9155018; DOI=10.1093/emboj/16.8.1921;
RA   Fukunaga R., Hunter T.;
RT   "MNK1, a new MAP kinase-activated protein kinase, isolated by a novel
RT   expression screening method for identifying protein kinase
RT   substrates.";
RL   EMBO J. 16:1921-1933(1997).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF MAPKAPK5.
RX   PubMed=9480836; DOI=10.1006/bbrc.1998.8135;
RA   Ni H., Wang X.S., Diener K., Yao Z.;
RT   "MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated
RT   protein kinase, is a substrate of the extracellular-regulated kinase
RT   (ERK) and p38 kinase.";
RL   Biochem. Biophys. Res. Commun. 243:492-496(1998).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF CANX, AND INTERACTION WITH CANX.
RX   PubMed=10393181; DOI=10.1093/emboj/18.13.3655;
RA   Chevet E., Wong H.N., Gerber D., Cochet C., Fazel A., Cameron P.H.,
RA   Gushue J.N., Thomas D.Y., Bergeron J.J.;
RT   "Phosphorylation by CK2 and MAPK enhances calnexin association with
RT   ribosomes.";
RL   EMBO J. 18:3655-3666(1999).
RN   [16]
RP   DEPHOSPHORYLATION BY DUSP3.
RX   PubMed=10224087; DOI=10.1074/jbc.274.19.13271;
RA   Todd J.L., Tanner K.G., Denu J.M.;
RT   "Extracellular regulated kinases (ERK) 1 and ERK2 are authentic
RT   substrates for the dual-specificity protein-tyrosine phosphatase VHR.
RT   A novel role in down-regulating the ERK pathway.";
RL   J. Biol. Chem. 274:13271-13280(1999).
RN   [17]
RP   SUBCELLULAR LOCATION, INTERACTION WITH MAP2K1/MEK1, AND DOMAIN.
RX   PubMed=10521408; DOI=10.1074/jbc.274.43.30349;
RA   Rubinfeld H., Hanoch T., Seger R.;
RT   "Identification of a cytoplasmic-retention sequence in ERK2.";
RL   J. Biol. Chem. 274:30349-30352(1999).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF DUSP1.
RX   PubMed=10617468; DOI=10.1126/science.286.5449.2514;
RA   Brondello J.M., Pouyssegur J., McKenzie F.R.;
RT   "Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-
RT   dependent phosphorylation.";
RL   Science 286:2514-2517(1999).
RN   [19]
RP   INTERACTION WITH HSF1.
RX   PubMed=10747973; DOI=10.1074/jbc.M000958200;
RA   Dai R., Frejtag W., He B., Zhang Y., Mivechi N.F.;
RT   "c-Jun NH2-terminal kinase targeting and phosphorylation of heat shock
RT   factor-1 suppress its transcriptional activity.";
RL   J. Biol. Chem. 275:18210-18218(2000).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF IER3, INTERACTION WITH IER3, AND ENZYME
RP   REGULATION.
RX   PubMed=12356731; DOI=10.1093/emboj/cdf488;
RA   Garcia J., Ye Y., Arranz V., Letourneux C., Pezeron G., Porteu F.;
RT   "IEX-1: a new ERK substrate involved in both ERK survival activity and
RT   ERK activation.";
RL   EMBO J. 21:5151-5163(2002).
RN   [21]
RP   INTERACTION WITH NISCH.
RX   PubMed=11912194; DOI=10.1074/jbc.M111838200;
RA   Sano H., Liu S.C.H., Lane W.S., Piletz J.E., Lienhard G.E.;
RT   "Insulin receptor substrate 4 associates with the protein IRAS.";
RL   J. Biol. Chem. 277:19439-19447(2002).
RN   [22]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF GRB10.
RX   PubMed=15952796; DOI=10.1021/bi050413i;
RA   Langlais P., Wang C., Dong L.Q., Carroll C.A., Weintraub S.T., Liu F.;
RT   "Phosphorylation of Grb10 by mitogen-activated protein kinase:
RT   identification of Ser150 and Ser476 of human Grb10zeta as major
RT   phosphorylation sites.";
RL   Biochemistry 44:8890-8897(2005).
RN   [24]
RP   INTERACTION WITH DAPK1.
RX   PubMed=15616583; DOI=10.1038/sj.emboj.7600510;
RA   Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F.,
RA   Chen R.H.;
RT   "Bidirectional signals transduced by DAPK-ERK interaction promote the
RT   apoptotic effect of DAPK.";
RL   EMBO J. 24:294-304(2005).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF ATF2.
RX   PubMed=12110590; DOI=10.1093/emboj/cdf361;
RA   Ouwens D.M., de Ruiter N.D., van der Zon G.C., Carter A.P.,
RA   Schouten J., van der Burgt C., Kooistra K., Bos J.L., Maassen J.A.,
RA   van Dam H.;
RT   "Growth factors can activate ATF2 via a two-step mechanism:
RT   phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69
RT   through RalGDS-Src-p38.";
RL   EMBO J. 21:3782-3793(2002).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2.
RX   PubMed=12974390; DOI=10.1515/BC.2003.134;
RA   Wu Y., Chen Z., Ullrich A.;
RT   "EGFR and FGFR signaling through FRS2 is subject to negative feedback
RT   control by ERK1/2.";
RL   Biol. Chem. 384:1215-1226(2003).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF BTG2.
RX   PubMed=15788397; DOI=10.1074/jbc.M500318200;
RA   Hong J.W., Ryu M.S., Lim I.K.;
RT   "Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces
RT   Pin-1 binding in cytoplasm and cell death.";
RL   J. Biol. Chem. 280:21256-21263(2005).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH HSF4.
RX   PubMed=16581800; DOI=10.1128/MCB.26.8.3282-3294.2006;
RA   Hu Y., Mivechi N.F.;
RT   "Association and regulation of heat shock transcription factor 4b with
RT   both extracellular signal-regulated kinase mitogen-activated protein
RT   kinase and dual-specificity tyrosine phosphatase DUSP26.";
RL   Mol. Cell. Biol. 26:3282-3294(2006).
RN   [30]
RP   PHOSPHORYLATION.
RX   PubMed=17274988; DOI=10.1016/j.febslet.2007.01.039;
RA   Degoutin J., Vigny M., Gouzi J.Y.;
RT   "ALK activation induces Shc and FRS2 recruitment: Signaling and
RT   phenotypic outcomes in PC12 cells differentiation.";
RL   FEBS Lett. 581:727-734(2007).
RN   [31]
RP   INTERACTION WITH ARRB2.
RX   PubMed=18435604; DOI=10.1042/BJ20080685;
RA   Xu T.-R., Baillie G.S., Bhari N., Houslay T.M., Pitt A.M., Adams D.R.,
RA   Kolch W., Houslay M.D., Milligan G.;
RT   "Mutations of beta-arrestin 2 that limit self-association also
RT   interfere with interactions with the beta2-adrenoceptor and the ERK1/2
RT   MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2
RT   MAPKs.";
RL   Biochem. J. 413:51-60(2008).
RN   [32]
RP   INTERACTION WITH ADAM15.
RX   PubMed=18296648; DOI=10.1158/1541-7786.MCR-07-2028;
RA   Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M.,
RA   Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C.,
RA   Edwards D.R.;
RT   "Distinct functions of natural ADAM-15 cytoplasmic domain variants in
RT   human mammary carcinoma.";
RL   Mol. Cancer Res. 6:383-394(2008).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   INTERACTION WITH TPR.
RX   PubMed=18794356; DOI=10.1128/MCB.00925-08;
RA   Vomastek T., Iwanicki M.P., Burack W.R., Tiwari D., Kumar D.,
RA   Parsons J.T., Weber M.J., Nandicoori V.K.;
RT   "Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites
RT   and docking domain on the nuclear pore complex protein Tpr
RT   cooperatively regulate ERK2-Tpr interaction.";
RL   Mol. Cell. Biol. 28:6954-6966(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [37]
RP   FUNCTION IN KIT SIGNALING PATHWAY, AND PHOSPHORYLATION.
RX   PubMed=19265199; DOI=10.1074/jbc.M808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [38]
RP   PHOSPHORYLATION AT TYR-204, AND DEPHOSPHORYLATION AT TYR-204 BY PTPRJ.
RX   PubMed=19494114; DOI=10.1074/jbc.M109.002758;
RA   Sacco F., Tinti M., Palma A., Ferrari E., Nardozza A.P.,
RA   Hooft van Huijsduijnen R., Takahashi T., Castagnoli L., Cesareni G.;
RT   "Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the
RT   RAS pathway by direct dephosphorylation of ERK1/2 kinases.";
RL   J. Biol. Chem. 284:22048-22058(2009).
RN   [39]
RP   INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M.,
RA   Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role
RT   of SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-198, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [41]
RP   PHOSPHORYLATION AT THR-207, ENZYME REGULATION, SUBUNIT, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19060905; DOI=10.1038/nm.1893;
RA   Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J.;
RT   "A new type of ERK1/2 autophosphorylation causes cardiac
RT   hypertrophy.";
RL   Nat. Med. 15:75-83(2009).
RN   [42]
RP   REVIEW ON FUNCTION.
RX   PubMed=16393692; DOI=10.1080/02699050500284218;
RA   Yoon S., Seger R.;
RT   "The extracellular signal-regulated kinase: multiple substrates
RT   regulate diverse cellular functions.";
RL   Growth Factors 24:21-44(2006).
RN   [43]
RP   REVIEW ON FUNCTION, AND REVIEW ON SUBCELLULAR LOCATION.
RX   PubMed=19565474; DOI=10.1002/biof.52;
RA   Yao Z., Seger R.;
RT   "The ERK signaling cascade--views from different subcellular
RT   compartments.";
RL   BioFactors 35:407-416(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [47]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21779493; DOI=10.1177/1947601911407328;
RA   Wortzel I., Seger R.;
RT   "The ERK cascade: distinct functions within various subcellular
RT   organelles.";
RL   Genes Cancer 2:195-209(2011).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [49]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [50]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-202 AND TYR-204, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [52]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=24825908; DOI=10.1074/jbc.M114.547208;
RA   Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R.;
RT   "Collaborator of ARF (CARF) regulates proliferative fate of human
RT   cells by dose-dependent regulation of DNA damage signaling.";
RL   J. Biol. Chem. 289:18258-18269(2014).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.39 ANGSTROMS), AND PHOSPHORYLATION AT
RP   TYR-204.
RX   PubMed=18983981; DOI=10.1016/j.bbrc.2008.10.127;
RA   Kinoshita T., Yoshida I., Nakae S., Okita K., Gouda M., Matsubara M.,
RA   Yokota K., Ishiguro H., Tada T.;
RT   "Crystal structure of human mono-phosphorylated ERK1 at Tyr204.";
RL   Biochem. Biophys. Res. Commun. 377:1123-1127(2008).
RN   [54]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway.
CC       MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important
CC       role in the MAPK/ERK cascade. They participate also in a signaling
CC       cascade initiated by activated KIT and KITLG/SCF. Depending on the
CC       cellular context, the MAPK/ERK cascade mediates diverse biological
CC       functions such as cell growth, adhesion, survival and
CC       differentiation through the regulation of transcription,
CC       translation, cytoskeletal rearrangements. The MAPK/ERK cascade
CC       plays also a role in initiation and regulation of meiosis,
CC       mitosis, and postmitotic functions in differentiated cells by
CC       phosphorylating a number of transcription factors. About 160
CC       substrates have already been discovered for ERKs. Many of these
CC       substrates are localized in the nucleus, and seem to participate
CC       in the regulation of transcription upon stimulation. However,
CC       other substrates are found in the cytosol as well as in other
CC       cellular organelles, and those are responsible for processes such
CC       as translation, mitosis and apoptosis. Moreover, the MAPK/ERK
CC       cascade is also involved in the regulation of the endosomal
CC       dynamics, including lysosome processing and endosome cycling
CC       through the perinuclear recycling compartment (PNRC); as well as
CC       in the fragmentation of the Golgi apparatus during mitosis. The
CC       substrates include transcription factors (such as ATF2, BCL6,
CC       ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as
CC       CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of
CC       apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG),
CC       regulators of translation (such as EIF4EBP1) and a variety of
CC       other signaling-related molecules (like ARHGEF2, FRS2 or GRB10).
CC       Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2,
CC       RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2,
CC       RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases
CC       (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which
CC       enable the propagation the MAPK/ERK signal to additional cytosolic
CC       and nuclear targets, thereby extending the specificity of the
CC       cascade. {ECO:0000269|PubMed:10393181,
CC       ECO:0000269|PubMed:10617468, ECO:0000269|PubMed:12110590,
CC       ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:12974390,
CC       ECO:0000269|PubMed:15788397, ECO:0000269|PubMed:15952796,
CC       ECO:0000269|PubMed:16581800, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:8325880, ECO:0000269|PubMed:9155018,
CC       ECO:0000269|PubMed:9480836}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2
CC       on Thr-202 and Tyr-204 in response to external stimuli like
CC       insulin or NGF. Both phosphorylations are required for activity.
CC       This phosphorylation causes dramatic conformational changes, which
CC       enable full activation and interaction of MAPK1/ERK2 with its
CC       substrates. Dephosphorylated and inactivated by DUSP3, DUSP6 and
CC       DUSP9. {ECO:0000269|PubMed:12356731, ECO:0000269|PubMed:19060905}.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates
CC       in multimolecular complexes. Found in a complex with at least
CC       BRAF, HRAS, MAP2K1/MEK1, MAPK3 and RGS14 (By similarity). Binds to
CC       HIV-1 Nef through its SH3 domain. This interaction inhibits its
CC       tyrosine-kinase activity. Interacts with ADAM15, ARRB2, CANX,
CC       DAPK1 (via death domain), HSF4, IER3, MAP2K1/MEK1, MORG1, NISCH,
CC       and SGK1. Interacts with PEA15 and MKNK2 (By similarity). MKNK2
CC       isoform 1 binding prevents from dephosphorylation and inactivation
CC       (By similarity). Interacts with TPR. Interacts with CDKN2AIP.
CC       Interacts with HSF1 (via D domain and preferentially with
CC       hyperphosphorylated form); this interaction occurs upon heat shock
CC       (PubMed:10747973). {ECO:0000250, ECO:0000269|PubMed:10393181,
CC       ECO:0000269|PubMed:10521408, ECO:0000269|PubMed:10747973,
CC       ECO:0000269|PubMed:11912194, ECO:0000269|PubMed:12356731,
CC       ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:16581800,
CC       ECO:0000269|PubMed:18296648, ECO:0000269|PubMed:18435604,
CC       ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:19060905,
CC       ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:24825908,
CC       ECO:0000269|PubMed:8794306}.
CC   -!- INTERACTION:
CC       P53355:DAPK1; NbExp=5; IntAct=EBI-73995, EBI-358616;
CC       P49366:DHPS; NbExp=3; IntAct=EBI-73995, EBI-741925;
CC       P28562:DUSP1; NbExp=3; IntAct=EBI-73995, EBI-975493;
CC       P19419:ELK1; NbExp=2; IntAct=EBI-73995, EBI-726632;
CC       Q02750:MAP2K1; NbExp=2; IntAct=EBI-73995, EBI-492564;
CC       P28482:MAPK1; NbExp=3; IntAct=EBI-73995, EBI-959949;
CC       Q16539:MAPK14; NbExp=5; IntAct=EBI-73995, EBI-73946;
CC       Q9EPI6:Nsmf (xeno); NbExp=2; IntAct=EBI-73995, EBI-6899705;
CC       P14618-1:PKM; NbExp=3; IntAct=EBI-73995, EBI-4304679;
CC       Q8N490:PNKD; NbExp=4; IntAct=EBI-73995, EBI-746368;
CC       P23467:PTPRB; NbExp=2; IntAct=EBI-73995, EBI-1265766;
CC       Q12913:PTPRJ; NbExp=5; IntAct=EBI-73995, EBI-2264500;
CC       Q62132:Ptprr (xeno); NbExp=3; IntAct=EBI-73995, EBI-6954051;
CC       Q15349:RPS6KA2; NbExp=2; IntAct=EBI-73995, EBI-1384149;
CC       Q14160:SCRIB; NbExp=2; IntAct=EBI-73995, EBI-357345;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Autophosphorylation
CC       at Thr-207 promotes nuclear localization.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P27361-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P27361-2; Sequence=VSP_041906;
CC       Name=3; Synonyms=ERK1b;
CC         IsoId=P27361-3; Sequence=VSP_041907;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC       {ECO:0000269|PubMed:10521408}.
CC   -!- PTM: Phosphorylated upon KIT and FLT3 signaling (By similarity).
CC       Dually phosphorylated on Thr-202 and Tyr-204, which activates the
CC       enzyme. Ligand-activated ALK induces tyrosine phosphorylation.
CC       Dephosphorylated by PTPRJ at Tyr-204. {ECO:0000250,
CC       ECO:0000269|PubMed:17274988, ECO:0000269|PubMed:18983981,
CC       ECO:0000269|PubMed:19060905, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:19494114}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK3ID425ch16p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X60188; CAA42744.1; -; mRNA.
DR   EMBL; AY033607; AAK52329.1; -; mRNA.
DR   EMBL; DQ399291; ABD60302.1; -; mRNA.
DR   EMBL; EU332853; ABY87542.1; -; Genomic_DNA.
DR   EMBL; AC012645; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471238; EAW79912.1; -; Genomic_DNA.
DR   EMBL; CH471238; EAW79915.1; -; Genomic_DNA.
DR   EMBL; BC013992; AAH13992.1; -; mRNA.
DR   EMBL; M84490; AAA36142.1; -; mRNA.
DR   EMBL; Z11696; CAA77754.1; -; mRNA.
DR   CCDS; CCDS10672.1; -. [P27361-1]
DR   CCDS; CCDS42148.1; -. [P27361-2]
DR   CCDS; CCDS42149.1; -. [P27361-3]
DR   PIR; A48082; A48082.
DR   RefSeq; NP_001035145.1; NM_001040056.2. [P27361-3]
DR   RefSeq; NP_001103361.1; NM_001109891.1. [P27361-2]
DR   RefSeq; NP_002737.2; NM_002746.2. [P27361-1]
DR   UniGene; Hs.861; -.
DR   PDB; 2ZOQ; X-ray; 2.39 A; A/B=1-379.
DR   PDB; 4QTB; X-ray; 1.40 A; A/B=1-379.
DR   PDBsum; 2ZOQ; -.
DR   PDBsum; 4QTB; -.
DR   ProteinModelPortal; P27361; -.
DR   SMR; P27361; -.
DR   BioGrid; 111581; 192.
DR   DIP; DIP-30985N; -.
DR   IntAct; P27361; 89.
DR   MINT; MINT-99599; -.
DR   STRING; 9606.ENSP00000263025; -.
DR   BindingDB; P27361; -.
DR   ChEMBL; CHEMBL3385; -.
DR   DrugBank; DB04604; 5-iodotubercidin.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB02733; Purvalanol.
DR   DrugBank; DB00605; Sulindac.
DR   GuidetoPHARMACOLOGY; 1494; -.
DR   iPTMnet; P27361; -.
DR   PhosphoSitePlus; P27361; -.
DR   BioMuta; MAPK3; -.
DR   DMDM; 232066; -.
DR   EPD; P27361; -.
DR   MaxQB; P27361; -.
DR   PaxDb; P27361; -.
DR   PeptideAtlas; P27361; -.
DR   PRIDE; P27361; -.
DR   DNASU; 5595; -.
DR   Ensembl; ENST00000263025; ENSP00000263025; ENSG00000102882. [P27361-1]
DR   Ensembl; ENST00000322266; ENSP00000327293; ENSG00000102882. [P27361-2]
DR   Ensembl; ENST00000395199; ENSP00000378625; ENSG00000102882. [P27361-3]
DR   Ensembl; ENST00000395202; ENSP00000378628; ENSG00000102882. [P27361-2]
DR   GeneID; 5595; -.
DR   KEGG; hsa:5595; -.
DR   UCSC; uc002dws.4; human. [P27361-1]
DR   CTD; 5595; -.
DR   DisGeNET; 5595; -.
DR   GeneCards; MAPK3; -.
DR   HGNC; HGNC:6877; MAPK3.
DR   HPA; CAB002683; -.
DR   HPA; HPA003995; -.
DR   HPA; HPA005700; -.
DR   HPA; HPA030069; -.
DR   MIM; 601795; gene.
DR   neXtProt; NX_P27361; -.
DR   OpenTargets; ENSG00000102882; -.
DR   PharmGKB; PA30622; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   eggNOG; ENOG410XNY0; LUCA.
DR   GeneTree; ENSGT00550000074298; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P27361; -.
DR   KO; K04371; -.
DR   OMA; RAPCADS; -.
DR   OrthoDB; EOG091G08QL; -.
DR   PhylomeDB; P27361; -.
DR   TreeFam; TF105097; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112409; RAF-independent MAPK1/3 activation.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-162658; Golgi Cisternae Pericentriolar Stack Reorganization.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-202670; ERKs are inactivated.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-73728; RNA Polymerase I Promoter Opening.
DR   Reactome; R-HSA-74749; Signal attenuation.
DR   Reactome; R-HSA-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P27361; -.
DR   SIGNOR; P27361; -.
DR   EvolutionaryTrace; P27361; -.
DR   GeneWiki; MAPK3; -.
DR   GenomeRNAi; 5595; -.
DR   PRO; PR:P27361; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000102882; -.
DR   CleanEx; HS_MAPK3; -.
DR   ExpressionAtlas; P27361; baseline and differential.
DR   Genevisible; P27361; HS.
DR   GO; GO:0005901; C:caveola; TAS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0031143; C:pseudopodium; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0097110; F:scaffold protein binding; IEA:Ensembl.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0061308; P:cardiac neural crest cell development involved in heart development; IEA:Ensembl.
DR   GO; GO:0051216; P:cartilage development; IEA:Ensembl.
DR   GO; GO:0072584; P:caveolin-mediated endocytosis; TAS:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IDA:CAFA.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:1903351; P:cellular response to dopamine; IMP:CAFA.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0060425; P:lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0000189; P:MAPK import into nucleus; IEA:Ensembl.
DR   GO; GO:2000657; P:negative regulation of apolipoprotein binding; IEA:Ensembl.
DR   GO; GO:0042473; P:outer ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0031281; P:positive regulation of cyclase activity; IMP:CACAO.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IMP:BHF-UCL.
DR   GO; GO:0033129; P:positive regulation of histone phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IEA:Ensembl.
DR   GO; GO:1905050; P:positive regulation of metallopeptidase activity; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:0006461; P:protein complex assembly; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; IEA:Ensembl.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; TAS:Reactome.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0070849; P:response to epidermal growth factor; IDA:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:CAFA.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   GO; GO:0006361; P:transcription initiation from RNA polymerase I promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008349; MAPK_ERK1/2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01770; ERK1ERK2MAPK.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Cell cycle; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Host-virus interaction; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.8}.
FT   CHAIN         2    379       Mitogen-activated protein kinase 3.
FT                                /FTId=PRO_0000186251.
FT   DOMAIN       42    330       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      48     56       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       202    204       TXY.
FT   ACT_SITE    166    166       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      71     71       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.8}.
FT   MOD_RES     198    198       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     202    202       Phosphothreonine; by MAP2K1 and MAP2K2.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     204    204       Phosphotyrosine; by MAP2K1 and MAP2K2.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:18983981,
FT                                ECO:0000269|PubMed:19494114}.
FT   MOD_RES     207    207       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19060905}.
FT   MOD_RES     263    263       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P28482}.
FT   MOD_RES     265    265       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P28482}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P28482}.
FT   VAR_SEQ     259    302       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041906.
FT   VAR_SEQ     340    379       PVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP
FT                                -> VGQSPAAVGLGAGEQGGT (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_041907.
FT   VARIANT     323    323       E -> K (in dbSNP:rs55859133).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042253.
FT   CONFLICT    174    174       I -> S (in Ref. 1; CAA42744 and 2;
FT                                AAK52329). {ECO:0000305}.
FT   STRAND       29     31       {ECO:0000244|PDB:4QTB}.
FT   STRAND       34     36       {ECO:0000244|PDB:4QTB}.
FT   TURN         39     41       {ECO:0000244|PDB:4QTB}.
FT   STRAND       42     51       {ECO:0000244|PDB:4QTB}.
FT   STRAND       54     61       {ECO:0000244|PDB:4QTB}.
FT   TURN         62     65       {ECO:0000244|PDB:4QTB}.
FT   STRAND       66     73       {ECO:0000244|PDB:4QTB}.
FT   HELIX        79     94       {ECO:0000244|PDB:4QTB}.
FT   STRAND      105    107       {ECO:0000244|PDB:4QTB}.
FT   TURN        112    114       {ECO:0000244|PDB:4QTB}.
FT   STRAND      118    122       {ECO:0000244|PDB:4QTB}.
FT   STRAND      126    128       {ECO:0000244|PDB:4QTB}.
FT   HELIX       129    135       {ECO:0000244|PDB:4QTB}.
FT   HELIX       140    159       {ECO:0000244|PDB:4QTB}.
FT   HELIX       169    171       {ECO:0000244|PDB:4QTB}.
FT   STRAND      172    174       {ECO:0000244|PDB:4QTB}.
FT   STRAND      180    182       {ECO:0000244|PDB:4QTB}.
FT   HELIX       193    195       {ECO:0000244|PDB:4QTB}.
FT   HELIX       208    210       {ECO:0000244|PDB:4QTB}.
FT   HELIX       213    215       {ECO:0000244|PDB:4QTB}.
FT   TURN        216    218       {ECO:0000244|PDB:4QTB}.
FT   HELIX       225    240       {ECO:0000244|PDB:4QTB}.
FT   HELIX       250    261       {ECO:0000244|PDB:4QTB}.
FT   HELIX       266    269       {ECO:0000244|PDB:4QTB}.
FT   HELIX       275    282       {ECO:0000244|PDB:4QTB}.
FT   HELIX       292    295       {ECO:0000244|PDB:4QTB}.
FT   HELIX       301    310       {ECO:0000244|PDB:4QTB}.
FT   HELIX       315    317       {ECO:0000244|PDB:4QTB}.
FT   HELIX       321    325       {ECO:0000244|PDB:4QTB}.
FT   HELIX       328    330       {ECO:0000244|PDB:4QTB}.
FT   TURN        331    333       {ECO:0000244|PDB:4QTB}.
FT   HELIX       336    338       {ECO:0000244|PDB:4QTB}.
FT   HELIX       350    354       {ECO:0000244|PDB:4QTB}.
FT   HELIX       357    368       {ECO:0000244|PDB:4QTB}.
FT   HELIX       369    371       {ECO:0000244|PDB:4QTB}.
SQ   SEQUENCE   379 AA;  43136 MW;  E6020CE413EC41F7 CRC64;
     MAAAAAQGGG GGEPRRTEGV GPGVPGEVEM VKGQPFDVGP RYTQLQYIGE GAYGMVSSAY
     DHVRKTRVAI KKISPFEHQT YCQRTLREIQ ILLRFRHENV IGIRDILRAS TLEAMRDVYI
     VQDLMETDLY KLLKSQQLSN DHICYFLYQI LRGLKYIHSA NVLHRDLKPS NLLINTTCDL
     KICDFGLARI ADPEHDHTGF LTEYVATRWY RAPEIMLNSK GYTKSIDIWS VGCILAEMLS
     NRPIFPGKHY LDQLNHILGI LGSPSQEDLN CIINMKARNY LQSLPSKTKV AWAKLFPKSD
     SKALDLLDRM LTFNPNKRIT VEEALAHPYL EQYYDPTDEP VAEEPFTFAM ELDDLPKERL
     KELIFQETAR FQPGVLEAP
//
